8-K current report · filed Sep 1, 2026

Biomarin Pharmaceutical Inc (BMRN) 8-K Current Report: September 1, 2026

Item 8.01BMRN overview

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 8.01 (Other Events). BioMarin completed its acquisition of Alesta Therapeutics on August 31, 2026.

Biomarin Pharmaceutical Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • BioMarin completed its acquisition of Alesta Therapeutics on August 31, 2026
  • Alesta is now a wholly owned BioMarin subsidiary
  • Transaction execution shifts Alesta from external asset to BioMarin-controlled operations
  • Investors should monitor subsequent filings for purchase consideration and financial statement impacts

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biomarin Pharmaceutical Inc 8-K filings

Get the next BMRN 8-K as it lands

Follow BMRN for push alerts, or ask the research agent what this filing means.